Vanda Pharmaceuticals stock's explosive rally may be more hype than substance

Core Insights - Vanda Pharmaceuticals experienced a significant stock price increase of approximately 45% following the FDA's approval of its treatment for schizophrenia and bipolar I disorder [1] Company Summary - The FDA has granted approval for Vanda Pharmaceuticals' treatment, which is expected to enhance the company's market position in the psychiatric treatment sector [1]